GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

China National Accord Medicines Corp 000028.SZ · CNY

Health Care · Shenzhen · 🇨🇳 China

Compare

21.32

-0.84%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥73.42bn

FY2016FY2025

Net income

CN¥1.14bn

FY2016FY2025

Free cash flow

CN¥1.42bn

FY2016FY2025

Shareholders' equity

CN¥18.61bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueCN¥73.42bnCN¥74.38bnCN¥75.48bnCN¥73.44bnCN¥68.36bnCN¥59.65bnCN¥52.79bnCN¥43.12bnCN¥41.26bnCN¥41.25bn
Research and developmentCN¥20.0mCN¥24.6mCN¥26.8mCN¥9.1mCN¥7.7m——CN¥84.1m—CN¥43.7m
Operating incomeCN¥1.51bnCN¥1.51bnCN¥2.41bnCN¥2.50bnCN¥2.16bnCN¥2.16bnCN¥1.95bnCN¥1.78bnCN¥1.57bnCN¥1.66bn
Net incomeCN¥1.14bnCN¥642.5mCN¥1.60bnCN¥1.49bnCN¥1.34bnCN¥1.40bnCN¥1.27bnCN¥1.21bnCN¥1.06bnCN¥1.19bn
Diluted earnings per share2.041.152.872.673.123.292.992.832.473.27

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsCN¥49.10bnCN¥47.56bnCN¥47.57bnCN¥42.62bnCN¥42.78bnCN¥39.59bnCN¥33.52bnCN¥28.93bnCN¥22.34bnCN¥21.31bn
Cash and short-term investments—CN¥7.41bnCN¥6.50bnCN¥6.02bnCN¥5.13bnCN¥6.00bnCN¥8.88bnCN¥8.09bnCN¥4.19bnCN¥3.52bn
Total liabilitiesCN¥27.47bnCN¥26.80bnCN¥26.59bnCN¥23.17bnCN¥24.76bnCN¥22.71bnCN¥18.16bnCN¥15.02bnCN¥12.42bnCN¥12.40bn
Debt—CN¥4.39bnCN¥13.75bnCN¥3.52bnCN¥4.23bnCN¥3.70bnCN¥3.24bnCN¥2.64bnCN¥1.60bnCN¥1.55bn
Shareholders' equityCN¥18.61bnCN¥17.67bnCN¥17.41bnCN¥16.13bnCN¥14.92bnCN¥13.95bnCN¥12.81bnCN¥11.62bnCN¥9.40bnCN¥8.45bn
Shares outstanding557m559m557m557m428m427m424m428m428m363m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operationsCN¥1.64bnCN¥3.27bnCN¥2.94bnCN¥2.56bnCN¥1.66bnCN¥1.50bnCN¥2.00bnCN¥1.32bnCN¥1.29bnCN¥1.47bn
Capital spending−CN¥217.3m−CN¥282.7m−CN¥322.2m−CN¥322.2m−CN¥370.4m−CN¥293.8m−CN¥245.2m−CN¥255.5m−CN¥204.3m−CN¥265.9m
Free cash flowCN¥1.42bnCN¥2.99bnCN¥2.61bnCN¥2.24bnCN¥1.28bnCN¥1.21bnCN¥1.76bnCN¥1.07bnCN¥1.08bnCN¥1.21bn
Dividends paid−CN¥386.3m−CN¥603.8m−CN¥342.5m−CN¥256.9m−CN¥342.5m−CN¥256.9m−CN¥171.3m−CN¥273.8m−CN¥246.2m−CN¥246.7m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueCN¥18.44bnCN¥17.82bnCN¥18.29bnCN¥18.33bnCN¥18.50bnCN¥18.29bnCN¥17.91bnCN¥18.68bn
Operating incomeCN¥417.8mCN¥442.7mCN¥179.4mCN¥394.0mCN¥487.4mCN¥439.1mCN¥240.8mCN¥419.0m
Net incomeCN¥318.7mCN¥287.5mCN¥116.5mCN¥291.2mCN¥337.9mCN¥328.0m−CN¥423.0mCN¥322.1m
Diluted earnings per share0.570.520.210.520.610.59-0.760.58
Cash from operations———−CN¥425.0mCN¥1.83bn−CN¥1.82bn—CN¥513.0m
Capital spending−CN¥32.0m−CN¥26.0m−CN¥44.0m−CN¥58.0m−CN¥50.0m−CN¥64.0m−CN¥79.0m−CN¥64.0m
Free cash flow———−CN¥483.0mCN¥1.78bn−CN¥1.88bn—CN¥449.0m
Total assetsCN¥48.17bnCN¥49.12bnCN¥49.10bnCN¥50.56bnCN¥50.43bnCN¥50.02bnCN¥47.56bnCN¥51.98bn
Cash and short-term investments———CN¥5.65bnCN¥6.80bnCN¥5.54bnCN¥7.41bnCN¥5.43bn
Debt———CN¥12.87bnCN¥4.34bnCN¥3.73bnCN¥3.02bnCN¥4.30bn
Shareholders' equityCN¥18.87bnCN¥18.90bnCN¥18.61bnCN¥18.43bnCN¥18.14bnCN¥18.00bnCN¥17.67bnCN¥18.10bn

Financial ratios

Data as of 2 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Operating margin2.1%2.0%3.2%3.4%3.2%3.6%——
Net margin1.5%0.9%2.1%2.0%2.0%2.4%——
Return on equity6.1%3.6%9.2%9.2%9.0%10.1%——
Return on assets2.3%1.4%3.4%3.5%3.1%3.5%——
Free cash flow yield17.0%32.4%29.8%26.3%24.1%21.4%——
Revenue growth-1.3%-1.5%2.8%7.4%14.6%13.0%——
Earnings growth76.8%-59.8%7.6%11.2%-4.7%10.6%——
Current ratio1.54x1.52x1.49x1.51x1.42x1.44x——
Debt to equity—0.17x0.71x0.14x0.19x0.12x0.11x—
Equity ratio37.9%37.2%36.6%37.8%34.9%35.2%——
Interest coverage7.78x5.11x8.46x9.53x7.52x7.26x——
R&D as a share of sales0.0%0.0%0.0%0.0%0.0%——0.2%
Buybacks as a share of market value0.4%-0.4%0.0%-30.1%-0.2%-0.7%——

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-0.0%4.2%6.9%
Operating income-15.4%-6.9%2.1%
Net income-8.6%-4.1%2.0%

Average margins

Over each period

1 year3 years5 years10 years
Operating margin2.0%2.7%2.9%3.2%
Net margin1.2%1.6%1.8%2.1%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings10.923.19.28.68.39.810.610.317.114.3
Price to sales0.20.20.20.20.20.20.30.30.40.4

Dividends and splits

Per share, in the currency the company pays

Paid for 17 years. Last went ex-dividend on 24 Jun 2026.

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Paid in the year0.6160.3330.6180.7270.420.5590.420.28
  • 13-for-10 split · 1 Jun 2023
  • 1-to-1 reverse split · 28 Apr 2006

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.